Dasatinib + Quercetin
Also known as: D+Q, senolytic combination
Status
No approved product. Dasatinib is approved as Sprycel for certain leukemias. There is no approved labeling for senolytic use of either agent, and no approved combination product.
What it is
A chemotherapy drug paired with a flavonoid, given in short intermittent courses in senolytic research.
What published research measured
The combination most used in senolytic research, given as short intermittent courses on a hit-and-run rationale: senescent cells are cleared and the drug is withdrawn, rather than taken continuously. Small open-label human trials in idiopathic pulmonary fibrosis and diabetic kidney disease reported reductions in markers of senescent cell burden. Dasatinib is a prescription tyrosine kinase inhibitor with a substantial toxicity profile of its own — pleural effusion, bleeding risk, cytopenias — and that profile does not disappear because the schedule is intermittent.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.